VIJAYA2022-01-012022-03-31in-bse-fin:OneOperatingExpenses01Member VIJAYA2022-01-012022-03-31in-bse-fin:FourOperatingExpenses01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares VIJAYA 2021-04-01 2022-03-31 2022-05-17 INR Lakhs Yearly true Cash Flow Indirect Single segment Diagnostic Services 2022-01-01 2022-03-31 Audited Standalone 1137405000.00 33116000.00 1170521000.00 174712000.00 0.00 0.00 187096000.00 43017000.00 151446000.00 304964000.00 861235000.00 309286000.00 0.00 309286000.00 81461000.00 -6871000.00 74590000.00 0.00 234696000.00 0.00 0.00 0.00 0.00 234696000.00 2483000.00 237179000.00 2483000.00 0.00 101966000.00 1 2.30 2.29 0.00 0.00 2.30 2.29 1. The above standalone financial results of Vijaya Diagnostic Centre Limited (Formerly known as 'Vijaya Diagnostic Centre Private Limited') ( the Company ) have been prepared in accordance with Indian Accounting Standards ( Ind AS ) prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with the relevant rules thereunder and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. 2. The Company has completed its Initial Public Offer ('IPO') and listed its equity shares on BSE Limited ('BSE') and National Stock Exchange of India Limited ('NSE') on 14 September 2021. Accordingly, the figures for the quarter ended 31 March 2021 as reported in these financial results were neither reviewed nor subject to audit. However, the management has exercised necessary due diligence to ensure that the financial results for these periods provide a true and fair view of the Company's affairs. The historical annual financial statements of the Company are available on the website of the Company at www.vijayadiagnostic.com. 3. The above standalone financial results were reviewed by the audit committee and approved by the Board of Directors in their respective meetings held on 26 May 2022. The statutory auditors have expressed an unmodified audit opinion on these results. 4. The standalone figures for the quarter ended 31 March 2022 are the balancing figures between the audited standalone figures in respect of the full financial year and the published unaudited year to date standalone figures up to the date of third quarter of the current financial year. 5. The Company’s operations fall within a single business segment “Diagnostic services”. 6. On 22 March 2021, the equity shares of the Company having the face value of Rs. 10 each were subdivided into 10 equity shares having a face value of Re. 1 each. Accordingly, 4,531,819 equity shares of face value of Rs. 10 each were subdivided into 45,318,190 equity shares of face value of Re. 1 each. The Company issued bonus shares on 27 May 2021 in proportion of five new equity shares of Re. 1 each for every four existing equity shares of Re. 1 each, resulting in total fully paid-up equity shares of 101,965,926 of Re. 1 each. The basic / diluted earnings per share have been adjusted towards this subdivision and bonus issue of shares for all the periods presented. 7. The Board of Directors at its meeting held on 26 May 2022, has proposed a final dividend of Re. 1 per equity share of Re. 1 each. 8. The outbreak of COVID-19 in many countries has brought about disruptions to businesses around the world and uncertainty to the global economy. The Company is closely monitoring the impact of the pandemic on all aspects of it’s business, including how it will impact its employees, vendors and business partners. The Company based on the information available to date, both internal and external, considered the uncertainty relating to the COVID-19 pandemic in assessing its impact on the financial results. Based on the current estimates, the Company expects to fully recover the carrying amount of assets, and does not foresee any material adverse impact on its operations. As the outbreak continues to evolve, the Company will continue to closely monitor any material changes to future economic condition. 9. The results of the Company are available for investors at www.vijayadiagnostic.com, www.nseindia.com and www.bseindia.com 10. Previous period figures have been regrouped / rearranged wherever considered necessary. Single segment 2021-04-01 2022-03-31 Audited Standalone 4508793000.00 129171000.00 4637964000.00 689521000.00 0.00 0.00 686766000.00 162556000.00 521365000.00 1133948000.00 3194156000.00 1443808000.00 0.00 1443808000.00 388061000.00 -25300000.00 362761000.00 0.00 1081047000.00 0.00 0.00 0.00 0.00 1081047000.00 1910000.00 1082957000.00 1910000.00 0.00 101966000.00 1 0.00 10.60 10.54 0.00 0.00 10.60 10.54 Other expenses 304964000.00 Other expenses 1133948000.00 147056000.00 -16020000.00 -29355000.00 0.00 -56411000.00 0.00 0.00 -28809000.00 0.00 3338000.00 0.00 0.00 0.00 521365000.00 0.00 18181000.00 0.00 51556000.00 0.00 0.00 0.00 99024000.00 11356000.00 -13625000.00 0.00 -4762000.00 0.00 -1814000.00 0.00 503032000.00 1946840000.00 0.00 0.00 0.00 391726000.00 0.00 1555114000.00 0.00 0.00 0.00 247694000.00 0.00 0.00 0.00 0.00 14139000.00 1220993000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 124394000.00 201000.00 72500000.00 15000000.00 0.00 0.00 0.00 120678000.00 0.00 0.00 0.00 -1267177000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 247167000.00 0.00 0.00 0.00 0.00 0.00 -247167000.00 40770000.00 0.00 40770000.00 63132000.00 103902000.00